**Author details**

Brygida Kwiatkowska and Maria Maślińska\*

\*Address all correspondence to: maslinskam@gmail.com

Institute of Rheumatology, Poland

#### **References**


[16] Saag, K. G., Teng, G. G., Patkar, N. M., & Et, al. (2008). American College of Rheuma‐ tology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum.; , 59, 762-784.

**References**

224 Common Eye Infections

*matism*, 58(1), 15-25.

793-800.

31(3), 594-597.

[1] Helmic, C. G., Felson, D. T., Lawrence, R. C., et al. (2008). Estimates of prevalence of arthritis and other rheumatic conditions in the United States. *Part 1. Arthritis & Rheu‐*

[2] Knox, S. A., Harrison, C. M., Britt, H. C., et al. (2008). Estimating prevalence of com‐ mon chronic morbidities in Australia. *Medical Journal of Australia*, 189(2), 66-70. [3] Symmons, D., Turner, G., Webb, R., et al. (2002). The prevalence of rheumatoid ar‐ thritis in the United Kingdom: New estimates for a new century. *Rheumatology*, 41(7),

[4] Simonnson, M., Bergman, S., Jacobsson, L. T. H., et al. (1999). The prevalence of rheu‐ matoid arthritis in Sweden. *Scandinavian Journal of Rheumatology*, 28(6), 340-343. [5] Senna, E. R., De Barros, A. L. P., Silva, E. O., et al. (2004). Prevalence of rheumatoid diseases in Brazil: a study using the COPCORD approach. *Journal of Rheumatology*,

[6] Darmawan, J., Muirden, K. D., Valkenburg, H. A., et al. (1993). The epidemiology of rheumatoid arthritis in Indonesia. *British Journal of Rheumatology*, 32(7), 537-540. [7] Aletaha, D., Neogi, T., Silman, A. J., et al. (2010). Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheuma‐

[8] Cimmino, M. A., Salvarani, C., & Macchioni, P. (2000). Extra-articular manifestations

[9] Young, A., & Koduri, G. (2007). Extra-articular manifestations and complications of

[10] Balbir-Gurman, A., Yigla, M., Nahir, A. M., et al. (2006). Rheumatoid pleural effu‐

[11] Mac, Donald. W. J. Jr, Crawford, M. H., Klippel, J. H., et al. (1977). Echocardiographic assessment of cardiac structure and function in patients with rheumatoid arthritis.

[12] Genta, M. S., Genta, R. M., & Gabay, C. (2006). Systemic rheumatoid vasculitis: a re‐

[13] Bartels, C. M., & Bridges, A. J. (2010). Rheumatoid Vasculitis: Vanishing Menance or

[14] Harper, S. L., & Foster, C. S. (1998). The ocular manifestation of rheumatoid disease.

[15] Zlatanovic, G., Veselinovic, D., Cekic, S., et al. (2010). Ocular manifestation of rheu‐ matoid arthritis-different forms and frequency. *Bosn J Basic Med Sci*, 10, 323-327.

tism collaborative initiative. *Arthritis Rheum*, 62, 2569-2581.

rheumatoid arthritis. *Best Pract Clin Rheumatol*, 21(5), 907-927.

Target for New Treatments? *Curr Rheumatol Rep*, 12(6), 414-419.

of rheumatoid arthritis. *Rheumatol Int*, 19(6), 213-217.

sion. *Semin Arthritis Rheum*, 35, 368-378.

view. *Semin Arthritis Rheum*, 36, 88-98.

*Am J Med*, 63, 890-896.

*Int Ophtalmol Clin*, 38, 1-19.


[44] Le Guern, V., Mahr, A., Mouyhon, L., et al. (2004). Prevalence of systemic sclerosis in French multi-ethnic county. *Rheumatology*, 43(9), 1129-1137.

[30] von, Koskull. S., Truckenbrodt, H., Holle, R., et al. (2001). Incidence and prevalence of juvenile arthritis in an urban population of southern Germany: a prospective

[31] Riise, Ø. R., Handeland, K. S., Cvancarova, M., et al. (2008). Incidence and character‐ istics of arthritis in Norwegian children: a population-based study. *Pediatrics*, 121(2),

[32] Berk, A. T., Kocak, N., & Ünsal, E. (2001). Uveitie in Juvenile arthritis. *Ocular Immu‐*

[33] Dadoniene, J., Adamoviciute, D., Rugiene, R., et al. (2006). The prevalence of system‐ ic lupus erythematosus in Lithuania: the lowest rate in Northern Europe. *Lupus*,

[34] Govoni, M., Castellino, G., Bosi, S., et al. (2006). Incidence and prevalence of systemic

[35] Boyer, G. S., Templin, D. W., & Lanier, A. P. (1991). Rheumatic diseases in Alaskan Indians of the southeast coast: high prevalence of rheumatoid arthritis and systemic

[36] Hochberg, M. C. (1997). Updating te American College of Rheumatology revised cri‐ teria for the classification of systemic lupus erythematosus. *Arthritis Rheum*, 40,

[37] Jensen, J. L., Bergem, H. O., & Gilboe, I. M. (1999). Oral and ocular sicca symptoms and findings are prevalent in systemic lupus erythematosus. *J Oral Patho Med*, 28(7),

[38] Nguyen, Q.d., & Foster, C. S. (1998). Systemic lupus eruthematosus and the eye. *Int*

[39] Bowman, S. J., Ibrahim, G. H., Holmes, G., et al. (2004). Estimating the prevalence among Caucasian women of primary Sjögrem syndrome in two general practices in

[40] Kabsakal, Y., Kitapcioglu, G., Turk, T., et al. (2006). The prevalence of Sjögren syn‐ drome In adult women. *Scandinavian Journal of Rheumatology*, 35(5), 379-383.

[41] Sanchez-Guerrero, J., Perez-Dosal, M. R., et al. (2005). Prevalence of Sjögren syn‐ drome In ambulatory patients according to the American-European Consensus

[42] Vitali, C., Bombardieri, S., Jonsson, R., et al. (2002). Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-Eu‐

[43] Allcock, R. J., Forrest, I., Corris, P. A., et al. (2004). A study of prevalence of systemic

Birmingham, UK. *Scandinavian Journal of Rheumatology*, 33(1), 39-43.

lupus erythematosus in a district of north Italy. *Lupus*, 15(2), 110-113.

lupus erythematosus. *Journal of Rheumatology*, 18(10), 477-484.

study. *Ann Rheum Dis*, 60(10), 940-945.

299-306.

226 Common Eye Infections

*nol*, 9(4), 243-251.

15(8), 544-546.

725-734.

317-322.

*Ophtalmol Clin*, 38(1), 33-60.

Group criteria. *Rheumatology*, 44(2), 235-240.

ropean Consensus Group. *Ann Rheum Dis*, 61, 554-558.

sclerosis in northeast England. *Rheumatology*, 43(5), 596-602.


[76] Kwiatkowska, B., & Filipowicz-Sosnowska, A. (2009). Reactive arthritis. *Pol Arch Med. Wewn*, 119(1-2), 60-66.

[60] O'Duffy, J. D. (1990). Vasculitis in Behçet's disease. *Rheum Dis Clin North Am*, 16(2),

[61] Hayreh, S. S., Podhajsky, P. A., & Zimmerman, B. (1998). Ocular manifestations of

[62] Gordon, L.k., & Levin, L. A. (1998). Visual loss in giant cel arteritis. *JAMA*, 280(4),

[63] Omdal, R., Wildhagen, K., Hansen, T., et al. (2005). Anti-CD20 therapy of treatmentresistant Wegener's granulomatosis: favourable but temporary response. *Scandinavi‐*

[64] Cheung, C. M. G., Murray, P. I., & Savage, C. O. S. (2005). Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. *Br J Ophtalmol*, 89(11),

[65] Hamideh, F., & Prete, P. E. (2001). Ophtalmologic Manifestations of Rheumatic Dis‐

[66] Blaho, K. (1992). Non-steroidal anti-inflammatory drugs: current trends in pharma‐

[67] Lyle, W. M., & Hayhoe, D. A. (1976). A literature survey of the potentially adverse effects of the drugs commonly prescribed for the elderly. *J Am Optom Assoc*, 47(6),

[68] Mahoney, B. P. (1976). Rheumatologic disease and associated ocular manifestations. *J*

[69] Crues, A. F., Schachet, A. P., & Nicholl, J. (1985). Chloroquine retinopathy. *Ophtalmol‐*

[70] Grant, S., Greenseid, D. Z., & Leopold, I. H. (1989). Toxic retinopathies. *In: Duane TD,*

[71] Mc Cormic, S. A., Dibartolomeo, A. G., & Raju, V. F. (1985). Ocular chrysiasis. *Ophtal‐*

[72] Kincaid, M. C., Green, W. R., & Hoover, R. E. (1982). Ocular chrysiasis. *Arch Ophtal‐*

[73] Loprinzi, C. L., Love, R. R., Garrity, J. A., et al. (1990). Cyclophosphamide, Metho‐ trexate, and 5Fluorouracil (CMF)-Induced Ocular Toxicity. *Cancer Investigation*, 8(%),

[74] Kersey, J. P., & Broadway, D. C. (2006). Corticosteroid-induced glaucoma: a review

[75] Kuna, P. (1998). Longterm effects of steroid therapy. *Wiad Lek*, 51, 12-18.

giant cell arteritis. *Am J Ophtalmol*, 125(4), 506-520.

eases. *Seminars in Arthritis and Rheumatism*, 30(4), 217-241.

cology and therapeutics. *J Am Optom Assoc*, 63(12), 875-878.

*Jaeger EA editors. Clinical Ophtalmology.Philadelphia: Lippincott*.

*an Journal of Rheumatology*, 34(3), 229-232.

423-431.

228 Common Eye Infections

385-386.

1542.

768-778.

*Am Optom Assoc*, 47(6), 403-415.

*ogy* [928], 1127-1129.

*mology*, 92(10), 432-435.

*mol*, 100(11), 791-794.

of the literature. *Eye*, 20, 407-416.

459-465.

